Abstract:Abstract Introduction The European Medicines Agency (MEA) approved the use of a proteolytic enzymatic debriding agent enriched in bromelain in 2012. It has become a widely used non-surgical treatment alternative for the debridement of deep partial thickness to full thickness thermal burns. We will present our early experience with this product candidly. We will outline our sequential learning. Moreover, we will describe the pitfalls and lessons learned as well as demonstrate the evolution of our current practice guidelines. Methods This is a retrospective analysis of all patients treated with a bromelain based enzymatic debridement agent at a regional burn unit. 17 patients with a mean age of 44.53 years were treated with enzymatic debridement between April 2017 and April 2022. This period includes an 18 month pause where we did not use the product. We reviewed analgesia requirements, efficacy of debridement using the product, wound care post debridement (including the use of skin substitutes), skin grafting post application and overall outcomes. Results 17 patients were treated during this period. Nine patients had burns involving less than 5% TBSA, three patients had burns between 5 and 15% TBSA and five had burns greater than 15% TBSA. Of the 17 patients, 10 had the enzymatic debridement agent applied on the ward and seven had it applied in theatre. For the application of the product three patients had general anaesthesia, two had a combination of general and regional anaesthesia (e.g. spinal, axillary block), three had regional analgesia alone, seven received oral analgesia and ward based sedation and two received oral analgesia and ward based Methoxyflurane. 10 patients required skin grafting. One patient was treated with allograft post enzymatic debridement. One patient had their post enzymatic debridement wounds covered with Xenograft. The remainder had their post debridement wounds treated with dressings. There were three cases where the proteolytic agent failed to debride the burns. In the skin grafted group, 1 patient had complete graft loss. We will provide a narrative description and outline how each case contributed to the development of our current treatment algorithm. Conclusions We now believe that enzymatic debridement does have a real place within the armamentarium of burn wound excision with dermal preservation. Undoubtedly, there is a learning curve associated with its use. This must be considered by any service intending to adopt its use. Applicability of Research to Practice We support the use of bromelain enriched proteolytic enzymatic debriding agent in appropriate cases. With experience, it is likely to be useful in the management of many patients who sustain deep partial thickness to full thickness burns.

Fluorimetric ex vivo quantification of protease debriding efficacy on natural substrate

Debridement efficacy of serine protease and formulated cream by In Vitro assessment against artificial wound eschar

In Vivo Assessment of Protease Dynamics in Cutaneous Wound Healing by Degradomics Analysis of Porcine Wound Exudates

An in vitro tissue model for screening sustained release of phosphate-based therapeutic attenuation of pathogen-induced proteolytic matrix degradation

Development of a porcine hard-to-heal wound model: evaluation of a bromelain-based enzymatic debriding agent

Removal of necrotic tissue with an ananain-based enzyme-debriding preparation

771 Enzymatic Burn Wound Debridement: The Learning Curve

In Vitro Enzymatic Degradation of Tissue Grafts and Collagen Biomaterials by Matrix Metalloproteinases: Improving the Collagenase Assay.

Detection of human neutrophil elastase (HNE) on wound dressings as marker of inflammation

Development of a High-Throughput ex-Vivo Burn Wound Model Using Porcine Skin, and Its Application to Evaluate New Approaches to Control Wound Infection

Papain Covalent Immobilization in Bacterial Cellulose Films as a Wound Dressing

Validation of a rapid collagenase activity detection technique based on fluorescent quenched gelatin with synovial fluid samples

Clinical performance and safety of a debridement pad with abrasive and non-abrasive fibres

Development of a Stringent Ex Vivo-Burned Porcine Skin Wound Model to Screen Topical Antimicrobial Agents

A Tensioned Human Skin Explant Model Used for Preliminary Assessment of Chemexfoliant-Stimulated Bioeffects

A 10-Minute Prototype Assay for Tissue Degradation Monitoring in Clinical Specimens

In Situ Delivery of Fibrin-Based Hydrogels Prevents Contraction and Reduces Inflammation

Use of antibody-hapten complexes attached to optical sensor surfaces as a substrate for proteases: real-time biosensing of protease activity.

Anti-Scarring Drug Screening with Near-Infrared Molecular Probes Targeting Fibroblast Activation Protein-α.

A high-precision wound healing assay based on photosensitized culture substrates

Enzyme-sensing chitosan hydrogels